Acquisition / Expansion

Lupin Completes Acquisition of VISUfarma to Strengthen European Specialty Portfolio

NSE

lupin

BSE

500257

Lupin has completed the acquisition of VISUfarma, a European specialty pharma company focused on ophthalmology, strengthening its specialty care portfolio and expanding its presence across key European markets.

PRICE-SENSITIVE TRIGGER

Event: Completion of acquisition of VISUfarma

Type: Acquisition / Expansion

Impact: Positive

Immediate Effect: Enhances Lupin’s specialty portfolio and strengthens its European market presence with over 60 ophthalmology products.

What Happened ?

Lupin Limited announced the successful completion of its acquisition of VISUfarma B.V. from GHO Capital Partners. VISUfarma is a European specialty pharmaceutical company focused on ophthalmology.

This acquisition marks a significant step in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence across Europe.

Key Strategic Highlights

Acquisition of VISUfarma completed, a leading European ophthalmology-focused pharma company
Adds 60+ branded products across:
- Dry eye
- Glaucoma
- Retinal health
- Specialty nutraceuticals
Strengthens presence in:
- Italy
- UK
- Spain
- Germany
- France
Enhances ability to capture growing demand for eye care solutions
Backed by experienced team and strong local market expertise

Note: The acquisition is expected to be immediately accretive and aligned with Lupin’s specialty growth strategy.

Company Commentary

Acquisition adds a differentiated portfolio of 60+ innovative eye care products
Expected to be immediately accretive
Strengthens Lupin’s European footprint
Supports long-term specialty segment expansion strategy

Risk Analysis

Key Risks

Integration challenges across operations and geographies
Regulatory risks in European markets
Dependence on specialty segment growth
Currency fluctuation impact

Worst Case Scenario

Failure to integrate VISUfarma effectively could reduce expected synergies and impact profitability.

Risk Level: Medium

Official Exchange Filing: Lupin Limited